In a report released on May 23, Jason Gerberry from Bank of America Securities reiterated a Buy rating on Liquidia Technologies (LQDA – Research Report), with a price target of $25.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason Gerberry has given his Buy rating due to a combination of factors surrounding Liquidia Technologies’ recent developments. The approval of Yutrepia as a 505b2 alternative to Tyvaso marks a significant milestone, as it is now approved for treating both PAH and PH-ILD. The approval comes with a broad label, and the marketing strategy is expected to highlight its higher dosing capability and the unique PRINT drug delivery system.
Furthermore, the company’s communication suggests optimism about early market entry and broad coverage, with expectations of early adoption. The anticipated investor call is likely to provide more insights into pricing and payer access. Gerberry has increased the price objective to $25 per share, reflecting the belief that LQDA shares are undervalued relative to their peak sales potential. This combination of strategic positioning and market potential underpins the Buy rating.
In another report released on May 21, Needham also maintained a Buy rating on the stock with a $25.00 price target.